Pazufloxacin (T-3761) is a fluoroquinolone antibiotic targeting antibacterial applications. This compound, a novel quinolone derivative, has demonstrated robust and extensive antibacterial efficacy. Its effectiveness spans systemic, pulmonary, and urinary tract infections in mice, effectively combating both gram-positive and gram-negative bacteria, including strains resistant to quinolones such as Serratia marcescens and Pseudomonas aeruginosa. Compared to existing antibiotics like ofloxacin, ciprofloxacin, norfloxacin, and tosufloxacin, Pazufloxacin shows comparable or superior efficacy across various infection models. While slightly less effective than tosufloxacin against certain gram-positive infections, it remains potent against methicillin-resistant Staphylococcus aureus infections. Its broad-spectrum activity is further evidenced by minimum inhibitory concentrations (MICs) ranging from 0.39 to 6.25 micrograms/ml against various Staphylococcus aureus and Clostridium species, with minimum bactericidal concentrations (MBCs) typically equal to or within twofold of the MICs. Additionally, its 50% inhibitory concentrations for DNA gyrases from E. coli and P. aeruginosa stand at 0.88 and 1.9 micrograms/ml, respectively, underscoring its potent antibacterial mechanism of action.